Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases
- 2 December 2008
- journal article
- research article
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 2 (12) , 1575-1585
Abstract
Thyroid cancer incidence is increasing, and its diagnosis can be challenging. Fine needle biopsy, the principal clinical tool to make a tissue diagnosis, leads to inconclusive diagnoses in up to 30% of the cases, leading to surgery. Advances in proteomics are improving abilities to diagnose malignant conditions using small samples of tissue or body fluids. We hypothesized that analysis of serum growth factors would uncover diagnostically informative differences between benign and malignant thyroid conditions. Using xMAP profiling, we evaluated concentrations of 19 cytokines, chemokines, and growth factors. We used sera from 23 patients with cancer (Malignant group), 24 patients with benign nodular thyroid disease (Benign group), and 23 healthy subjects (Normal group). In univariate analysis, five factors (epithelial growth factor, hepatocyte growth factor, Interleukins‐5 and ‐8, and regulated upon activation, normally T‐expressed and presumably secreted (RANTES) distinguished subjects with thyroid disease from the Normal group. In multivariate analysis, the set {Interleukin‐8, hepatocyte growth factor, monocyte‐induced γ interferon, interleukin‐12 p40} achieved noteworthy discrimination between Benign and Malignant groups (area under the receiver operating characteristics curve was 0.81 (95% confidence interval: 0.65–0.90)). Multiplex panels of serum biomarkers may be promising tools to diagnose cancer in patients presenting with evidence of nodular thyroid disease.Keywords
Funding Information
- NIH/ NCI R01 (CA115902)
This publication has 46 references indexed in Scilit:
- Fine‐needle aspiration biopsy versus ultrasound‐guided fine‐needle aspiration biopsy: Cost‐effectiveness as a frontline diagnostic modality for solitary thyroid nodulesHead & Neck, 2008
- Alteration of Cellular and Humoral Immunity by Mutant p53 Protein and Processed Mutant Peptide in Head and Neck CancerClinical Cancer Research, 2007
- Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expressionExperimental Cell Research, 2007
- A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrappingEndocrine-Related Cancer, 2007
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006
- Long-term risks for thyroid cancer and other neoplasms after exposure to radiationNature Clinical Practice Endocrinology & Metabolism, 2005
- Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD InitiativeClinical Chemistry, 2003
- Epidemiology and Primary Prevention of Thyroid CancerThyroid®, 2002
- Lifestyle and Other Risk Factors for Thyroid Cancer in Los Angeles County FemalesAnnals of Epidemiology, 2002
- Cystic thyroid nodules. The dilemma of malignant lesionsArchives of internal medicine (1960), 1990